HYFTOR ® is for patients 6 years of age and older who have facial angiofibroma—one of the most visible signs of TSC. Ask your doctor if HYFTOR ® is right for you and when it will be available to help you treat your facial angiofibroma.

HYFTOR ® is a prescription medicine that is used on the skin (topical) to treat adults and children 6 years of age and older with a type of noncancerous tumor called angiofibroma on your face caused by the genetic condition tuberous sclerosis. It is not known if HYFTOR ® is safe and effective in children under 6 years of age.

HYFTOR ® is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients 6 years of age and older. Facial angiofibroma is one of the most visible manifestations of TSC. 1,2

HYFTOR ® is a prescription medicine that is used on the skin (topical) to treat adults and children 6 years of age and older with a type of noncancerous tumor called angiofibroma on your face caused by the genetic condition tuberous sclerosis.

HYFTOR ® is a prescription medicine that is used on the skin (topical) to treat adults and children 6 years of age and older with a type of noncancerous tumor called angiofibroma on your face caused by the genetic condition tuberous sclerosis. It is not known if HYFTOR ® is safe and effective in children under 6 years of age.

HYFTOR ® is the first and only topical medication approved by the FDA to treat facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and children 6 years and older. HYFTOR ® is a clear gel that contains an mTOR inhibitor.

HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.

HYFTOR ® is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older. Important Safety Information

HYFTOR® is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older. Important Safety Information

HYFTOR ® (sirolimus topical gel) 0.2% is commercially available in the U.S. by prescription as the first topical treatment indicated for facial angiofibroma associated with tuberous sclerosis complex in adults and children 6 years of age or older.